AAAAAA

   
Results: 1-25 | 26-50 | 51-53
Results: 26-50/53
DOSE-DEPENDENT INHIBITION OF CYP1A2, CYP2C19 AND CYP2D6 BY CITALOPRAM, FLUOXETINE, FLUVOXAMINE AND PAROXETINE
Authors: JEPPESEN U GRAM LF VISTISEN K LOFT S POULSEN HE BROSEN K
Citation: U. Jeppesen et al., DOSE-DEPENDENT INHIBITION OF CYP1A2, CYP2C19 AND CYP2D6 BY CITALOPRAM, FLUOXETINE, FLUVOXAMINE AND PAROXETINE, European Journal of Clinical Pharmacology, 51(1), 1996, pp. 73-78
IMPACT OF QUINIDINE ON PLASMA AND CEREBROSPINAL-FLUID CONCENTRATIONS OF CODEINE AND MORPHINE AFTER CODEINE INTAKE
Authors: SINDRUP SH HOFMANN U ASMUSSEN J MIKUS G BROSEN K NIELSEN F INGWERSEN SH CHRISTENSEN CB
Citation: Sh. Sindrup et al., IMPACT OF QUINIDINE ON PLASMA AND CEREBROSPINAL-FLUID CONCENTRATIONS OF CODEINE AND MORPHINE AFTER CODEINE INTAKE, European Journal of Clinical Pharmacology, 49(6), 1996, pp. 503-509
THE BIOTRANSFORMATION OF CLOMIPRAMINE IN-VITRO, IDENTIFICATION OF THECYTOCHROME P450S RESPONSIBLE FOR THE SEPARATE METABOLIC PATHWAYS
Authors: NIELSEN KK FLINOIS JP BEAUNE P BROSEN K
Citation: Kk. Nielsen et al., THE BIOTRANSFORMATION OF CLOMIPRAMINE IN-VITRO, IDENTIFICATION OF THECYTOCHROME P450S RESPONSIBLE FOR THE SEPARATE METABOLIC PATHWAYS, The Journal of pharmacology and experimental therapeutics, 277(3), 1996, pp. 1659-1664
THE HYPOALGESIC EFFECT OF TRAMADOL IN RELATION TO CYP2D6
Authors: POULSEN L ARENDTNIELSEN L BROSEN K SINDRUP SH
Citation: L. Poulsen et al., THE HYPOALGESIC EFFECT OF TRAMADOL IN RELATION TO CYP2D6, Clinical pharmacology and therapeutics, 60(6), 1996, pp. 636-644
CHLOROGUANIDE METABOLISM IN RELATION TO THE EFFICACY IN MALARIA PROPHYLAXIS AND THE S-MEPHENYTOIN OXIDATION IN TANZANIANS
Authors: SKJELBO E MUTABINGWA TK BYGBJERG I NIELSEN KK GRAM LF BROSEN K
Citation: E. Skjelbo et al., CHLOROGUANIDE METABOLISM IN RELATION TO THE EFFICACY IN MALARIA PROPHYLAXIS AND THE S-MEPHENYTOIN OXIDATION IN TANZANIANS, Clinical pharmacology and therapeutics, 59(3), 1996, pp. 304-311
THE PHARMACOGENETICS OF CODEINE HYPOALGESIA
Authors: SINDRUP SH BROSEN K
Citation: Sh. Sindrup et K. Brosen, THE PHARMACOGENETICS OF CODEINE HYPOALGESIA, Pharmacogenetics, 5(6), 1995, pp. 335-346
A MULTIFAMILY STUDY ON THE RELATIONSHIP BETWEEN CYP2C19 GENOTYPE AND S-MEPHENYTOIN OXIDATION PHENOTYPE
Authors: BROSEN K DEMORAIS SMF MEYER UA GOLDSTEIN JA
Citation: K. Brosen et al., A MULTIFAMILY STUDY ON THE RELATIONSHIP BETWEEN CYP2C19 GENOTYPE AND S-MEPHENYTOIN OXIDATION PHENOTYPE, Pharmacogenetics, 5(5), 1995, pp. 312-317
IMIPRAMINE METABOLISM IN RELATION TO THE SPARTEINE AND MEPHENYTOIN OXIDATION POLYMORPHISMS - A POPULATION STUDY
Authors: MADSEN H NIELSEN KK BROSEN K
Citation: H. Madsen et al., IMIPRAMINE METABOLISM IN RELATION TO THE SPARTEINE AND MEPHENYTOIN OXIDATION POLYMORPHISMS - A POPULATION STUDY, British journal of clinical pharmacology, 39(4), 1995, pp. 433-439
SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND THEOPHYLLINE METABOLISM IN HUMAN LIVER-MICROSOMES - POTENT INHIBITION BY FLUVOXAMINE
Authors: RASMUSSEN BB MAENPAA J PELKONEN O LOFT S POULSEN HE LYKKESFELDT J BROSEN K
Citation: Bb. Rasmussen et al., SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND THEOPHYLLINE METABOLISM IN HUMAN LIVER-MICROSOMES - POTENT INHIBITION BY FLUVOXAMINE, British journal of clinical pharmacology, 39(2), 1995, pp. 151-159
THE HYPOALGESIC EFFECT OF IMIPRAMINE IN DIFFERENT HUMAN EXPERIMENTAL PAIN MODELS
Authors: POULSEN L ARENDTNIELSEN L BROSEN K NIELSEN KK GRAM LF SINDRUP SH
Citation: L. Poulsen et al., THE HYPOALGESIC EFFECT OF IMIPRAMINE IN DIFFERENT HUMAN EXPERIMENTAL PAIN MODELS, Pain, 60(3), 1995, pp. 287-293
LACK OF RELATIONSHIP BETWEEN QUINIDINE PHARMACOKINETICS AND THE SPARTEINE OXIDATION POLYMORPHISM
Authors: NIELSEN F ROSHOLM JU BROSEN K
Citation: F. Nielsen et al., LACK OF RELATIONSHIP BETWEEN QUINIDINE PHARMACOKINETICS AND THE SPARTEINE OXIDATION POLYMORPHISM, European Journal of Clinical Pharmacology, 48(6), 1995, pp. 501-504
MOCLOBEMIDE, A SUBSTRATE OF CYP2C19 AND AN INHIBITOR OF CYP2C19, CYP2D6, AND CYP1A2 - A PANEL STUDY
Authors: GRAM LF GUENTERT TW GRANGE S VISTISEN K BROSEN K
Citation: Lf. Gram et al., MOCLOBEMIDE, A SUBSTRATE OF CYP2C19 AND AN INHIBITOR OF CYP2C19, CYP2D6, AND CYP1A2 - A PANEL STUDY, Clinical pharmacology and therapeutics, 57(6), 1995, pp. 670-677
DETERMINATION OF QUINIDINE, DIHYDROQUINIDINE, (3S)-3-HYDROXYQUINIDINEAND QUINIDINE N-OXIDE IN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
Authors: NIELSEN F NIELSEN KK BROSEN K
Citation: F. Nielsen et al., DETERMINATION OF QUINIDINE, DIHYDROQUINIDINE, (3S)-3-HYDROXYQUINIDINEAND QUINIDINE N-OXIDE IN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, Journal of chromatography B. Biomedical applications, 660(1), 1994, pp. 103-110
S-MEPHENYTOIN, SPARTEINE AND DEBRISOQUINE OXIDATION - GENETIC POLYMORPHISMS IN A TURKISH POPULATION
Authors: BASCI NE BROSEN K BOZKURT A ISIMER A SAYAL A KAYAALP SO
Citation: Ne. Basci et al., S-MEPHENYTOIN, SPARTEINE AND DEBRISOQUINE OXIDATION - GENETIC POLYMORPHISMS IN A TURKISH POPULATION, British journal of clinical pharmacology, 38(5), 1994, pp. 463-465
CYP2D6 GENOTYPE DETERMINATION IN THE DANISH POPULATION
Authors: BROSEN K NIELSEN PN BRUSGAARD K GRAM LF SKJODT K
Citation: K. Brosen et al., CYP2D6 GENOTYPE DETERMINATION IN THE DANISH POPULATION, European Journal of Clinical Pharmacology, 47(3), 1994, pp. 221-225
CYP2D6 GENOTYPE DETERMINATION IN THE DANISH POPULATION
Authors: BROSEN K NIELSEN PN BRUSGAARD K GRAM LF SKJODT K
Citation: K. Brosen et al., CYP2D6 GENOTYPE DETERMINATION IN THE DANISH POPULATION, European Journal of Clinical Pharmacology, 47(3), 1994, pp. 221-225
GLUCURONIDATION CLEARANCE OF 8-HYDROXYCLOMIPRAMINE IN RELATION TO SPARTEINE AND MEPHENYTOIN PHENOTYPE
Authors: NIELSEN KK BROSEN K HANSEN MGJ GRAM LF
Citation: Kk. Nielsen et al., GLUCURONIDATION CLEARANCE OF 8-HYDROXYCLOMIPRAMINE IN RELATION TO SPARTEINE AND MEPHENYTOIN PHENOTYPE, European Journal of Clinical Pharmacology, 47(2), 1994, pp. 209-210
SINGLE-DOSE KINETICS OF CLOMIPRAMINE - RELATIONSHIP TO THE SPARTEINE AND S-MEPHENYTOIN OXIDATION POLYMORPHISMS
Authors: NIELSEN KK BROSEN K HANSEN MGJ GRAM LF
Citation: Kk. Nielsen et al., SINGLE-DOSE KINETICS OF CLOMIPRAMINE - RELATIONSHIP TO THE SPARTEINE AND S-MEPHENYTOIN OXIDATION POLYMORPHISMS, Clinical pharmacology and therapeutics, 55(5), 1994, pp. 518-527
REVERSIBLE INTERACTION OF MOCLOBEMIDE WITH CYP2D6 AND CYP2C9
Authors: GUENTERT TW GRAM LF GRANGE S BROSEN K
Citation: Tw. Guentert et al., REVERSIBLE INTERACTION OF MOCLOBEMIDE WITH CYP2D6 AND CYP2C9, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 137-137
DETERMINATION OF THEOPHYLLINE METABOLITES IN HUMAN LIVER-MICROSOMES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
Authors: RASMUSSEN BB NIELSEN KK BROSEN K
Citation: Bb. Rasmussen et al., DETERMINATION OF THEOPHYLLINE METABOLITES IN HUMAN LIVER-MICROSOMES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, Analytical biochemistry, 222(1), 1994, pp. 9-13
THE PHARMACOGENETICS OF THE SELECTIVE SEROTONIN REUPTAKE INHIBITORS
Authors: BROSEN K
Citation: K. Brosen, THE PHARMACOGENETICS OF THE SELECTIVE SEROTONIN REUPTAKE INHIBITORS, The Clinical investigator, 71(12), 1993, pp. 1002-1009
PROGUANIL METABOLISM IS DETERMINED BY THE MEPHENYTOIN OXIDATION POLYMORPHISM IN VIETNAMESE LIVING IN DENMARK
Authors: BROSEN K SKJELBO E FLACHS H
Citation: K. Brosen et al., PROGUANIL METABOLISM IS DETERMINED BY THE MEPHENYTOIN OXIDATION POLYMORPHISM IN VIETNAMESE LIVING IN DENMARK, British journal of clinical pharmacology, 36(2), 1993, pp. 105-108
MOCLOBEMIDE TREATMENT CAUSES A SUBSTANTIAL RISE IN THE SPARTEINE METABOLIC RATIO
Authors: GRAM LF BROSEN K
Citation: Lf. Gram et K. Brosen, MOCLOBEMIDE TREATMENT CAUSES A SUBSTANTIAL RISE IN THE SPARTEINE METABOLIC RATIO, British journal of clinical pharmacology, 35(6), 1993, pp. 649-652
ARE POOR METABOLIZERS OF SPARTEINE DEBRISOQUINE LESS PAIN TOLERANT THAN EXTENSIVE METABOLIZERS
Authors: SINDRUP SH POULSEN L BROSEN K ARENDTNIELSEN L GRAM LF
Citation: Sh. Sindrup et al., ARE POOR METABOLIZERS OF SPARTEINE DEBRISOQUINE LESS PAIN TOLERANT THAN EXTENSIVE METABOLIZERS, Pain, 53(3), 1993, pp. 335-339
MOCLOBEMIDE - A REVERSIBLE MAO-A-INHIBITOR SHOWING WEAKER ANTIDEPRESSANT EFFECT THAN CLOMIPRAMINE IN A CONTROLLED MULTICENTER STUDY
Authors: GLUE P CHRISTENSEN P LOLK A ANDERSEN E RASK P KRAGHSORENSEN P HANSEN JB VILMAR T LAURITZEN L LOLDRUP D LABIANCA J CLEMMESEN L THORUP M BECH P BUTLER B ODUM K KLYSNER R BOLWIG TG AAGAARD J NORGAARD B SORENSEN C SIMONSEN C MERINDER L WELTER H BARTELS U NIELSEN JA WEEKE A ANDERSEN SJ SOGAARD HJ VESTERGAARD P REISBY N SCHEPELERN S ESCHEN F LARSEN JK HANSEN H BRODSGAARD M HANSEN PEB KNUDSEN AF SCHMIDT J KRAGHSORENSEN P BECH P BOLWIG TG VESTERGAARD P GRAM LF NIELSEN KK BROSEN K KUHN H
Citation: P. Glue et al., MOCLOBEMIDE - A REVERSIBLE MAO-A-INHIBITOR SHOWING WEAKER ANTIDEPRESSANT EFFECT THAN CLOMIPRAMINE IN A CONTROLLED MULTICENTER STUDY, Journal of affective disorders, 28(2), 1993, pp. 105-116
Risultati: 1-25 | 26-50 | 51-53